Profil Institute For Clinical Research, Inc.
Chula Vista, California, 91911, United States
NCT Number: NCT01165268
It is anticipated that 7 days of oral administration of 10 mg dapagliflozin will reduce the renal glucose reabsorption similarly in healthy subjects and in subjects with T2DM.
Looking for future studies?
Notify Me18 year–65 year
All sexes
Interventional
Phase 1
Chula Vista, California, 91911, United States
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
for T2DM
Inclusion criteria
for healthy subjects:
Inclusion criteria
for all subjects:
Exclusion criteria
for all subjects:
Tablets, Oral, 10 mg, Once daily, 7 days
Time frame: Before 7 days of oral administration of 10 mg of dapagliflozin
Time frame: After 7 days of oral administration of 10 mg of dapagliflozin
Time frame: Before 7 days of oral administration of 10 mg of dapagliflozin
Time frame: After 7 days of oral administration of 10 mg of dapagliflozin
Time frame: Study Day 7
Time frame: Study Day 8
AstraZeneca
Industry
Characterization of the Kinetics of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and in Subjects With Type 2 Diabetes Mellitus
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT03899883
Diabetes, Diabetes Complications
Aurora, Colorado, United States
View Trial DetailsNCT05313529
Cognition Disorders, Cognitive Dysfunction
Changzhou, Jiangsu, China
View Trial DetailsNCT05684341
Diabetes Mellitus, Diabetes Mellitus, Type 2
Changhua, Taiwan
View Trial DetailsNCT07255820
Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Diabetes Mellitus
Karachi, Sindh, Pakistan
View Trial Details